What are RANKL inhibitor drugs?

RANKL inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting RANKL). 0 are currently marketed, with 4 more in clinical development.

RANKL inhibitor

0 marketed 3 in Phase 3 1 in Phase 2

This page covers all RANKL inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting RANKL.

Targets

RANKL

Phase 3 pipeline (3)

ABP 234 · Amgen · Bone metabolism / Oncology
ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
ABP 959 · Amgen · Bone metabolism / Oncology
ABP 959 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
ABP 938 · Amgen · Bone metabolism / Osteoporosis
ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.

Phase 2 pipeline (1)

AMG 162 - Prolia · Amgen · Bone disorders
AMG 162, also known as Prolia, is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.